Search

Your search keyword '"Gradishar, William J."' showing total 457 results
Start Over Author "Gradishar, William J." Language english
457 results on '"Gradishar, William J."'

1. A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)

Author

Mezzanotte-Sharpe, Jessica, ONeill, Anne, Mayer, Ingrid A., Arteaga, Carlos L., Yang, Ximing J., Wagner, Lynne I., Cella, David, Meropol, Neal J., Alpaugh, R. Katherine, Saphner, Thomas J., Swaney, Robert E., Hoelzer, Karen L., Gradishar, William J., Abramson, Vandana G., Sundaram, P. Kothai, Jilani, Shamim Z., Perez, Edith A., Lin, Nancy U., Jahanzeb, Mohammad, Wolff, Antonio C., Sledge, George W., and Reid, Sonya A.

Published
2024
Full Text
View/download PDF

2. Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes

Author

Lenz, Lauren, Neff, Chris, Solimeno, Cara, Cogan, Elizabeth S., Abramson, Vandana G., Boughey, Judy C., Falkson, Carla, Goetz, Matthew P., Ford, James M., Gradishar, William J., Jankowitz, Rachel C., Kaklamani, Virginia G., Marcom, P. Kelly, Richardson, Andrea L., Storniolo, Anna Maria, Tung, Nadine M., Vinayak, Shaveta, Hodgson, Darren R., Lai, Zhongwu, Dearden, Simon, Hennessy, Bryan T., Mayer, Erica L., Mills, Gordon B., Slavin, Thomas P., Gutin, Alexander, Connolly, Roisin M., Telli, Melinda L., Stearns, Vered, Lanchbury, Jerry S., and Timms, Kirsten M.

Published
2023
Full Text
View/download PDF

3. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)

Author

Cardoso, Fatima, Paluch-Shimon, Shani, Schumacher-Wulf, Eva, Matos, Leonor, Gelmon, Karen, Aapro, Matti S., Bajpai, Jyoti, Barrios, Carlos H., Bergh, Jonas, Bergsten-Nordström, Elizabeth, Biganzoli, Laura, Cardoso, Maria João, Carey, Lisa A., Chavez-MacGregor, Mariana, Chidebe, Runcie, Cortés, Javier, Curigliano, Giuseppe, Dent, Rebecca A., El Saghir, Nagi S., Eniu, Alexandru, Fallowfield, Lesley, Francis, Prudence A., Franco Millan, Sandra X., Gilchrist, Jenny, Gligorov, Joseph, Gradishar, William J., Haidinger, Renate, Harbeck, Nadia, Hu, Xichun, Kaur, Ranjit, Kiely, Belinda, Kim, Sung-Bae, Koppikar, Smruti, Kuper-Hommel, Marion J.J., Lecouvet, Frédéric E., Mason, Ginny, Mertz, Shirley A., Mueller, Volkmar, Myerson, Claire, Neciosup, Silvia, Offersen, Birgitte V., Ohno, Shinji, Pagani, Olivia, Partridge, Ann H., Penault-Llorca, Frédérique, Prat, Aleix, Rugo, Hope S., Senkus, Elzbieta, Sledge, George W., Swain, Sandra M., Thomssen, Christoph, Vorobiof, Daniel A., Vuylsteke, Peter, Wiseman, Theresa, Xu, Binghe, Costa, Alberto, Norton, Larry, and Winer, Eric P.

Published
2024
Full Text
View/download PDF

4. Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis

Author

Gerratana, Lorenzo, Davis, Andrew A., Velimirovic, Marko, Clifton, Katherine, Hensing, Whitney L., Shah, Ami N., Dai, Charles S., Reduzzi, Carolina, D’Amico, Paolo, Wehbe, Firas, Medford, Arielle, Wander, Seth A., Gradishar, William J., Behdad, Amir, Puglisi, Fabio, Ma, Cynthia X., Bardia, Aditya, and Cristofanilli, Massimo

Published
2023
Full Text
View/download PDF

5. Pharmacological suppression of the OTUD4/CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers

Author

Zhu, Yueming, Banerjee, Anupam, Xie, Ping, Ivanov, Andrey A., Uddin, Amad, Jiao, Qiao, Chi, Junlong Jack, Zeng, Lidan, Lee, Ji Young, Xue, Yifan, Lu, Xinghua, Cristofanilli, Massimo, Gradishar, William J., Henry, Curtis J., Gillespie, Theresa W., Bhave, Manali Ajay, Kalinsky, Kevin, Fu, Haian, Bahar, Ivet, Zhang, Bin, and Wan, Yong

Subjects
Proteolysis -- Analysis -- Health aspects, Immunosuppression -- Analysis -- Health aspects, Health care industry
Abstract

Despite widespread utilization of immunotherapy, treating immune-cold tumors remains a challenge. Multiomic analyses and experimental validation identified the OTUD4/CD73 proteolytic axis as a promising target in treating immune-suppressive triple negative breast cancer (TNBC). Mechanistically, deubiquitylation of CD73 by OTUD4 counteracted its ubiquitylation by TRIM21, resulting in CD73 stabilization inhibiting tumor immune responses. We further demonstrated the importance of TGF-[beta] signaling for orchestrating the OTUD4/CD73 proteolytic axis within tumor cells. Spatial transcriptomics profiling discovered spatially resolved features of interacting malignant and immune cells pertaining to expression levels of OTUD4 and CD73. In addition, ST80, a newly developed inhibitor, specifically disrupted proteolytic interaction between CD73 and OTUD4, leading to reinvigoration of cytotoxic [CD8.sup.+] T cell activities. In preclinical models of TNBC, ST80 treatment sensitized refractory tumors to anti-PD-LI therapy. Collectively, our findings uncover what we believe to be a novel strategy for targeting the immunosuppressive OTUD4/CD73 proteolytic axis in treating immune-suppressive breast cancers with the inhibitor ST80., Introduction Despite the widespread utilization of immunotherapy, the poor clinical response by immune-suppressive tumors is an emerging challenge in use of current immune checkpoint inhibitors. Triple negative breast cancers (TNBCs) [...]

Published
2024
Full Text
View/download PDF

7. Improving the Outcome of Bad-Acting Hormone Receptor-Positive Breast Cancer.

Author

Gradishar, William J.

Subjects
*HORMONE receptor positive breast cancer, *BREAST cancer, *EPIDERMAL growth factor receptors, *METASTATIC breast cancer, *HORMONES
Abstract

The article discusses the advancements in the treatment of estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer, focusing on combining endocrine therapy with cyclin-dependent kinase 4/6 inhibitors, phosphoinositide 3-kinase inhibitors, and selective estrogen-receptor degraders. Topics include the effectiveness of cyclin-dependent kinase 4/6 inhibitors, PI3K pathway-targeted therapy in patients with PIK3CA mutations, and clinical trial outcomes.

Published
2024
Full Text
View/download PDF

8. Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis

Author

Gerratana, Lorenzo, Davis, Andrew A., Velimirovic, Marko, Reduzzi, Carolina, Clifton, Katherine, Bucheit, Leslie, Hensing, Whitney L., Shah, Ami N., Pivetta, Tania, Dai, Charles S., DʼAmico, Paolo, Wehbe, Firas, Medford, Arielle, Wander, Seth A., Gradishar, William J., Behdad, Amir, Ma, Cynthia X., Puglisi, Fabio, Bardia, Aditya, and Cristofanilli, Massimo

Published
2023
Full Text
View/download PDF

12. Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium

Author

Dietz, Jill R., Moran, Meena S., Isakoff, Steven J., Kurtzman, Scott H., Willey, Shawna C., Burstein, Harold J., Bleicher, Richard J., Lyons, Janice A., Sarantou, Terry, Baron, Paul L., Stevens, Randy E., Boolbol, Susan K., Anderson, Benjamin O., Shulman, Lawrence N., Gradishar, William J., Monticciolo, Debra L., Plecha, Donna M., Nelson, Heidi, and Yao, Katharine A.

Published
2020
Full Text
View/download PDF

15. Coping strategies and psychosocial resources among women living with metastatic breast cancer: A qualitative study.

Author

Noriega Esquives, Blanca S., Walsh, Emily A., Penedo, Frank J., Thomas, Jessica L., Horner, Fiona S., Torzewski, Joanna B., Gradishar, William J., Victorson, David E., and Moreno, Patricia I.

Subjects
PSYCHOTHERAPY, QUALITATIVE research, FOCUS groups, STRESS management, OPTIMISM, GROUP identity, BREAST tumors, POSITIVE psychology, CANCER, MINDFULNESS, PSYCHOLOGY of women, PSYCHOLOGICAL adaptation, TREATMENT effectiveness, ATTITUDE (Psychology), MEDICAL research, RELIGION, SOCIAL support, INTERPERSONAL relations, PATIENTS' attitudes, AVOIDANCE (Psychology)
Abstract

Objective: Despite more women living with metastatic breast cancer (MBC), this population is underrepresented in cancer survivorship research. Few studies have assessed how women with MBC cope with their cancer experience. This qualitative study describes the coping strategies and psychosocial resources utilized by women living with MBC.Methods: Twenty-two women with MBC participated in four focus groups. Transcripts were analyzed using a general inductive approach. Codes derived from participants' responses were subsequently condensed into themes.Results: We identified 12 coping strategies and psychosocial resources and grouped them into five themes: Behavioral Coping Strategies (i.e. stress management, active coping and planning); Cognitive Coping Strategies and Psychological Resources (i.e. cognitive reappraisal, optimism, mindfulness, positive thinking, and religious coping); Existential Approach-Oriented Coping (i.e. acceptance, values-based living, and identity integration); Avoidance (i.e. avoidant coping); and Interpersonal Resources and Seeking Social Support (i.e. social support).Conclusions: Women living with MBC utilize several engagement and disengagement coping strategies, as well as intrapersonal and interpersonal resources. This study provides useful perspectives of women living with MBC that may inform the development of psychosocial interventions. Further research is needed to assess coping strategies and psychosocial resources across different subgroups of MBC patients and determine their impact on cancer outcomes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Novel Neoadjuvant Treatment Strategies for Triple-Negative Breast Cancer

Author

Davis, Andrew A. and Gradishar, William J.

Subjects
Carboplatin, Cancer -- Adjuvant treatment, Progesterone, Breast cancer -- Care and treatment, Health
Abstract

Introduction Triple-negative breast cancer (TNBC), which accounts for approximately 10% to 15% of breast cancers, remains the most aggressive subtype and is characterized by early disease relapse for a subset [...]

Published
2020

20. RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer

Author

Baselga, José, Zamagni, Claudio, Gómez, Patricia, Bermejo, Begoña, Nagai, Shigenori E., Melichar, Bohuslav, Chan, Arlene, Mángel, Lászlo, Bergh, Jonas, Costa, Frederico, Gómez, Henry L., Gradishar, William J., Hudis, Clifford A., Rapoport, Bernardo L., Roché, Henri, Maeda, Patricia, Huang, Liping, Meinhardt, Gerold, Zhang, Joshua, and Schwartzberg, Lee S.

Published
2017
Full Text
View/download PDF

23. Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial

Author

Rugo, Hope S, Im, Seock-Ah, Cardoso, Fatima, Cortes, Javier, Curigliano, Giuseppe, Musolino, Antonino, Pegram, Mark D, Bachelot, Thomas, Wright, Gail S, Saura, Cristina, Escrivá-de-Romaní, Santiago, De Laurentiis, Michelino, Schwartz, Gary N, Pluard, Timothy J, Ricci, Francesco, Gwin, William R, Levy, Christelle, Brown-Glaberman, Ursa, Ferrero, Jean-Marc, de Boer, Maaike, Kim, Sung-Bae, Petráková, Katarína, Yardley, Denise A, Freedman, Orit, Jakobsen, Erik H, Gal-Yam, Einav Nili, Yerushalmi, Rinat, Fasching, Peter A, Kaufman, Peter A, Ashley, Emily J, Perez-Olle, Raul, Hong, Shengyan, Rosales, Minori Koshiji, Gradishar, William J, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Institut Català de la Salut, [Rugo HS] University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA. [Im SA] Cancer Research Institute, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, South Korea. [Cardoso F] Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal. [Cortes J] Quironsalud Group, International Breast Cancer Center (IBCC), Madrid and Barcelona, Spain. Department of Medicine, Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Madrid, Spain. [Curigliano G] Istituto Europeo di Oncologia, IRCCS, University of Milano, Milan, Italy. [Musolino A] Department of Medicine and Surgery, University of Parma, Parma, Italy. Medical Oncology and Breast Unit, University Hospital of Parma, Parma, Italy. Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Parma, Italy. [Saura C, Escrivá-de-Romaní S] Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Cancer Research, neoplasias::neoplasias por localización::neoplasias de la mama [ENFERMEDADES], Oncology, Anticossos monoclonals - Ús terapèutic, Otros calificadores::/uso terapéutico [Otros calificadores], Neoplasms::Neoplasms by Site::Breast Neoplasms [DISEASES], Mama - Càncer - Tractament, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales::anticuerpos monoclonales humanizados [COMPUESTOS QUÍMICOS Y DROGAS], Other subheadings::/therapeutic use [Other subheadings], Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Humanized [CHEMICALS AND DRUGS], Other subheadings::Other subheadings::/drug therapy [Other subheadings]
Abstract

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Final overall survival (OS) in SOPHIA (ClinicalTrials.gov identifier: NCT02492711 ), a study of margetuximab versus trastuzumab, both with chemotherapy, in patients with previously treated human epidermal growth factor receptor 2–positive advanced breast cancer, is reported with updated safety. Overall, 536 patients in the intention-to-treat population were randomly assigned to margetuximab (15 mg/kg intravenously once every 3 weeks; n = 266) plus chemotherapy or trastuzumab (6 mg/kg intravenously once every 3 weeks after a loading dose of 8 mg/kg; n = 270) plus chemotherapy. Primary end points were progression-free survival, previously reported, and OS. Final OS analysis was triggered by 385 prespecified events. The median OS was 21.6 months (95% CI, 18.89 to 25.07) with margetuximab versus 21.9 months (95% CI, 18.69 to 24.18) with trastuzumab (hazard ratio [HR], 0.95; 95% CI, 0.77 to 1.17; P = .620). Preplanned, exploratory analysis of CD16A genotyping suggested a possible improvement in OS for margetuximab in CD16A-158FF patients versus trastuzumab (median OS, 23.6 v 19.2 months; HR, 0.72; 95% CI, 0.52 to 1.00) and a possible improvement in OS for trastuzumab in CD16A-158VV patients versus margetuximab (median OS, 31.1 v 22.0 months; HR, 1.77; 95% CI, 1.01 to 3.12). Margetuximab safety was comparable with trastuzumab. Final overall OS analysis did not demonstrate margetuximab advantage over trastuzumab. Margetuximab studies in patients with human epidermal growth factor receptor 2–positive breast cancer with different CD16A allelic variants are warranted.

Published
2023

25. Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer...

Author

Kalinsky, Kevin, Accordino, Melissa K., Chiuzan, Codruta, Mundi, Prabhjot S., Sakach, Elizabeth, Sathe, Claire, Ahn, Heejoon, Trivedi, Meghna S., Novik, Yelena, Tiersten, Amy, Raptis, George, Baer, Lea N., Oh, Sun Y., Zelnak, Amelia B., Wisinski, Kari B., Andreopoulou, Eleni, Gradishar, William J., Stringer-Reasor, Erica, Reid, Sonya A., and O'Dea, Anne

Published
2023
Full Text
View/download PDF

26. Margetuximab in HER2-positive metastatic breast cancer.

Author

Gradishar, William J, O'Regan, Ruth, Rimawi, Mothaffar F, Nordstrom, Jeffrey L, Rosales, Minori K, and Rugo, Hope S

Abstract

Several anti-HER2 agents are approved for third-line treatment and beyond (after first-line and second-line); however, no specific treatment strategy is recommended for third-line and beyond. Although these agents improve disease outcomes, HER2-positive metastatic breast cancer remains incurable and there is an unmet need for effective therapies in the later line setting. This review focuses on the development of margetuximab-cmkb, a novel, Fc-engineered, anti-HER2 monoclonal antibody, and its role in the systemic treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. In about 20% of patients with breast cancer, their tumor cells make too many copies of a protein called HER2. We call them HER2-positive breast cancer cells. HER2 is a protein that signals to breast cancer cells to make them grow. Certain drugs, known as antibodies, are able to bind to the HER2 proteins on the surface of the tumor cells. This stops their signaling and slows down the growth of the tumor cells. These antibodies are called anti-HER2 antibodies. In addition to its 'head' region binding to HER2, the 'tail' region of the anti-HER2 antibody can bind to certain other proteins (receptors) found on the surface of immune cells. When the anti-HER2 antibodies bind to the receptors on immune cells, this starts an anticancer immune response against the HER2-positive breast cancer cells and kills them. This review explains how anti-HER2 antibodies may block and destroy HER2-positive breast cancer cells. In particular, we focus on the beneficial and adverse effects of margetuximab, an anti-HER2 antibody. The tail region of margetuximab has been changed to boost the immune responses against HER2-positive cancer cells. Margetuximab is approved in the USA for patients with HER2-positive metastatic breast cancer after they have already received two or more anti-HER2 therapies. The decision to approve this was based on the pivotal clinical trial SOPHIA. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

28. Problem solving for breast health care delivery in low and middle resource countries (LMCs): consensus statement from the Breast Health Global Initiative

Author

Harford, Joe B., Otero, Isabel V., Anderson, Benjamin O., Cazap, Eduardo, Gradishar, William J., Gralow, Julie R., Kane, Gabrielle M., Niëns, Laurens M., Porter, Peggy L., Reeler, Anne V., Rieger, Paula T., Shockney, Lillie D., Shulman, Lawrence N., Soldak, Tanya, Thomas, David B., Thompson, Beti, Winchester, David P., Zelle, Sten G., and Badwe, Rajendra A.

Published
2011
Full Text
View/download PDF

30. Contributors

Author

Adesoye, Taiwo, Aebi, Stefan, Aizer, Ayal, Allweis, Tanir M., Arnold, Alicia Huff, Ashfaq, Raheela, Barrio, Andrea V., Bazan, Jose G., Bedrosian, Isabelle, Berkowitz, Alyssa, Bland, Kirby I., Aydi, Zeynep B., Braunstein, Lior Z., Brufsky, Adam, Cahlon, Oren, Carlson, Kjirsten A., Cass, Samuel, Cathcart-Rake, Elizabeth, Caudle, Abigail, Chen, Zhengshan, Chen, Chien, Childs, Daniel S., Chung, Alice, Cody, Hiram S., III, Coleman, Robert, Copeland, Edward M., III, Cox, Solange E., Cox, Dawn M., Czyz, Rebecca, David, Bre Ana, Degnim, Amy C., Dhakal, Ajay, Dietz, Jill R., Esgueva, Antonio J., Euhus, David M., Farr, Deborah E., Fayanju, Oluwadamilola M., Freedman, Gary M., Gallagher, Kristalyn K., Garvey, Patrick Bryan, Gass, Jennifer S., Geletzke, Abby K., Gemignani, Mary L., Giuliano, Armando E., Goldman, Kara N., Golshan, Mehra, Goodman, Chelain R., Gradishar, William J., Greenberg, Caprice C., Grobmyer, Stephen R., Grubstein, Ahuva, Gutnik, Lily, Harris, Eleanor E., Howard, Frederick M., Hunt, Kelly K., Jhawar, Sachin R., Jungheim, Emily S., Kaklamani, Virginia, Kalliath, Naomi J., Karuturi, Meghan S., Kass, Rena B., Khan, Seema A., Khan, Maryam I., Khan, Sadia, Suzanne Klimberg, V., Korourian, Soheila, Krishnamurthy, Jairam, Kuerer, Henry M., Kumarapeli, Asangi R., Kumbla, Pallavi A., Kumthekar, Priya, Lathrop, Kate I., Lee, Anne E., Marilyn Leitch, A., Liang, Diana, Lin, Nancy U., Linda Bi, Wenya, Lippe, Caroline E., Lu, Janice, Lustberg, Maryam, Ma, Emily, Ma, Yanling, Della Makower, Mallory, Melissa Anne, Mancino, Anne Thompson, Massoll, Nicole, Matalkah, Ahmad M., Matar, Regina, Mathew, Aju, McCormick, Beryl, McGuire, Kandace P., Mehra, Karishma, Mendez, Jane E., Menes, Tehillah, Merajver, Sofia D., Mhatre, Priya V., Mitchell, Sunny D., Morikawa, Aki, Muesse, Jason L., Nanda, Rita, Okoro, Stanley, O'Regan, Ruth M., Osipo, Clodia, Pariser, Ashley, Pastoriza, Jessica, Patel, Vijay, Pernas, Sonia, Piltin, Mara A., Pisano, Courtney E., Podoll, Mirna B., Post, Ginell R., Prati, Raquel, Press, Michael F., Pusztai, Lajos, Racz, Jennifer, Rivere, Amy E., Robinson, Angelica S., Rosenbloom, Arlan L., Rosso, Kelly J., Rozenblit, Mariya, Rubio, Isabel T., Ruddy, Kathryn J., Sanders, Melinda E., Sanft, Tara, Savalia, Nirav B., Schuetz, Steven J., Sener, Stephen F., Shah, Ami N., Shahpar, Samman, Shalin, Sara C., Siddiq, Namrah, Silverstein, Melvin J., Simpson, Ashley, Singhal, Dhruv, Smith, Benjamin D., Smith, Karen Lisa, Spanheimer, Philip M., Sparano, Joseph A., Spiguel, Lisa R.P., Stearns, Vered, Steliga, Matthew A., Sun, Susie X., Tarantino, Paolo, Tolaney, Sara M., De La Torre, Jorge I., Tsai, Jacqueline, Valente, Stephanie A., Sorice-Virk, Sarah, Vogel, Victor G., Wapnir, Irene L., Weiser, Roi, Yaney, Alex, Yellala, Amulya, and Zanfagnin, Valentina

Published
2024
Full Text
View/download PDF

43. Leveraging Molecular Information for Optimal Treatment Recommendations.

Author

Robinson, Patricia and Gradishar, William J.

Subjects
THERAPEUTIC use of antineoplastic agents, HORMONE receptor positive breast cancer, DRUG resistance in cancer cells, CANCER patient medical care, CELLULAR signal transduction, METASTASIS, ESTROGEN receptors, CANCER chemotherapy, MOLECULAR biology, ESTROGEN antagonists, CELL survival, EPIDERMAL growth factor receptors
Abstract

Not much longer than a decade ago, the approach to the treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer focused primarily on the sequential use of a limited number of endocrine agents, continuing until progressively shorter durations of progression-free intervals were observed, suggesting the emergence of endocrine-refractory disease. Although data were emerging to suggest molecular mechanisms of endocrine resistance, including deregulation of the ER pathway, alterations in cell survival signals, and activation of escape pathways, therapeutic strategies that could leverage these insights were not available. Thus, the approach was to pivot to chemotherapy for the remainder of a patient's journey through metastatic disease. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

45. Case 30-2008: a 47-year-old woman with a mass in the breast and a solitory lesion in the spine

Author

Gradishar, William J., Bellon, Jennifer R., Gadd, Michele A., D'Alessandro, Helen Anne, and Braaten, Kristina

Subjects
Breast cancer -- Diagnosis, Breast cancer -- Care and treatment
Abstract

A case study of a 47-year-old woman with a mass in the breast is discussed to better understand breast cancer and its diagnosis and management. Some of the different treatment methodologies for breast cancer are discussed.

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results